How common are approved EB-2 NIW petitions?

EB-2 NIW petition outcomes vary based on the strength of evidence, the specific criteria addressed, and the adjudicating officer. Each case is evaluated individually based on its own merits and documentation.

How does the Medicinal Chemistry industry affect EB-2 NIW petition outcomes?

The Medicinal Chemistry sector has unique considerations for EB-2 NIW petitions. USCIS evaluates whether the petitioner's qualifications and contributions align with the specific requirements of the visa category. Industry context matters for demonstrating the significance and impact of the petitioner's work.

approved EB-2 (NIW)

Scientist II, Medicinal Chemistry

Medicinal Chemistry · New Zealand · 2025-03-05

Processing Time

467 days

Decision Date

2025-03-05

Location

California

This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to design and optimize novel small-molecule therapeutics to improve cancer patient outcomes, specifically targeting difficult-to-treat cancers. Their work involves leveraging synthetic organic chemistry and catalysis to develop innovative approaches for constructing biologically active lead compounds with enhanced pharmacological profiles.

Framework Evaluation

3 of 3 criteria met

1 Substantial Merit and National Importance Met

The endeavor addresses critical national healthcare needs through the development of next-generation anticancer therapies.

2 Well-positioned to Advance the Endeavor Met

The petitioner's PhD, publication record in top-tier journals, and high citation count demonstrate their readiness to advance medicinal chemistry.

3 On Balance, Beneficial to Waive Job Offer Met

The petitioner's specialized expertise in small molecule synthesis provides a significant benefit to U.S. biomedical research leadership that outweighs the need for labor certification.

Why This Petition Was Approved

The petition was approved based on the petitioner's PhD and a record of 9 peer-reviewed publications with 146 citations, including two papers ranking in the top 10% of their field. The case was supported by 2 expert recommendation letters and evidence of the petitioner's role as a peer reviewer for academic journals. USCIS found that the petitioner satisfied all three Dhanasar prongs without the need for an RFE.

Evidence

Evidence Types

Peer Reviewed Publications

Citations

Reference Letters Dependent

Judging Experience

Original Contributions

Government Alignment

Similar Cases

Research Scientist

Biotechnology · India

WeGreened EB-2 (NIW) approved

Indiana 296 days 2025-02-24

The petitioner proposes to develop targeted cancer therapeutics and precision-based therapeutic options to prevent the recurrence of malignant diseases. The work focuses on creating cost-effective, personalized, and immunological therapies to simplify cancer diagnosis and treatment. The endeavor aims to improve treatment outcomes, reduce side effects, and lower long-term healthcare costs in the United States.

View Case

Postdoctoral Researcher

Pharmaceuticals · Bangladesh

WeGreened EB-2 (NIW) approved

Illinois 535 days 2026-01-16

The petitioner proposes to continue research in clinical pharmaceutical sciences, specifically focusing on understanding cancer development at the molecular level. The work involves investigating mechanisms such as genome instability and replication stress to identify actionable molecular targets for cost-conscious therapeutic strategies.

View Case

Postdoctoral Researcher

Research and Development · South Korea

WeGreened EB-2 (NIW) approved

California 174 days 2022-09-29

The petitioner proposes to continue identifying lead molecules to develop novel drugs for treating cancer, autoimmune diseases, addiction, neurodegenerative diseases, and viral infections. The work specifically focuses on translesion synthesis to support the development of targeted therapeutics that circumvent drug resistance in cancer patients.

View Case

Chemist

Pharmaceuticals · China

WeGreened EB-2 (NIW) rfe approved

Pennsylvania 364 days 2025-11-26

The petitioner proposes to develop practical and efficient synthetic routes to produce active pharmaceutical ingredients (APIs) for drugs currently in clinical trials. This work focuses on improving scalable production methods to reduce costs and shorten development timelines for new therapies targeting cancer and neurodegenerative disorders.

View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Pharmaceuticals cases More cases from New Zealand

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-03-05.

Browse all cases

View Original

At a Glance

Outcome approved

Processing 467 days

Criteria Met 3 / 3

Evidence Types 6

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,816

Success Rate 53.6%

Sustained 2,046

Dismissed 1,674

EB-2 (NIW) Overview EB-2 (NIW) in New Zealand All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist

Scientist II, Medicinal Chemistry

Proposed Endeavor

Framework Evaluation

Why This Petition Was Approved

Evidence

Similar Cases

Research Scientist

Postdoctoral Researcher

Postdoctoral Researcher

Chemist

Frequently Asked Questions

Browse More Cases

At a Glance

EB-2 (NIW) Case Data

Related Pages

Get Case Insights